ArticleBMC musculoskeletal disorders2022

Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP).

Bernard J Smilde et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.